OverviewSuggest Edit

Imara is a company, dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. The Company offers IMR-687, an oral, and selective phosphodiesterase 9 (PDE9) inhibitor to treat patients with sickle cell disease by both reducing red blood cell sickling and blockage of blood vessels that are underlying causes of the pathology of sickle cell disease.

TypePublic
Founded2015
HQBoston, MA, US
Websiteimaratx.com

Latest Updates

Employees (est.) (Feb 2020)20
Job Openings4
Share Price (Oct 2021)$3.6
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Imara

Rahul D. Ballal

Rahul D. Ballal

CEO, Director
Rahul Ballal

Rahul Ballal

President and Chief Executive Officer
Kenneth Attie

Kenneth Attie

Chief Medical Officer
Mike Gray

Mike Gray

Chief Financial and Chief Operating Officer
Lynette Hopkinson

Lynette Hopkinson

Senior Vice President of Regulatory
Stephen M. Migausky

Stephen M. Migausky

Senior Vice President, Legal and General Counsel
Show more

Imara Office Locations

Imara has an office in Boston
Boston, MA, US (HQ)
116 Huntington Ave 6th floor
Show all (1)

Imara Financials and Metrics

Imara Revenue

USD

Net income (FY, 2019)

(23.5m)

EBIT (FY, 2019)

(24.1m)

Market capitalization (21-Oct-2021)

63.5m

Closing stock price (21-Oct-2021)

3.6

Cash (31-Dec-2019)

4.9m
Imara's current market capitalization is $63.5 m.
USDFY, 2018FY, 2019

General and administrative expense

2.4m5.1m

R&D expense

8.2m19.0m

Operating expense total

10.7m24.1m

EBIT

(10.7m)(24.1m)
USDFY, 2018FY, 2019

Cash

7.4m4.9m

Prepaid Expenses

323.0k1.7m

Current Assets

7.7m30.6m

PP&E

442.0k
USDFY, 2018FY, 2019

Net Income

(11.3m)(23.5m)

Depreciation and Amortization

33.0k

Accounts Payable

477.0k750.0k

Cash From Operating Activities

(8.8m)(21.9m)
USDFY, 2018

Financial Leverage

-0.3 x
Show all financial metrics

Imara Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Imara Online and Social Media Presence

Embed Graph

Imara News and Updates

Imara to Participate in Upcoming Investor Conferences

SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference

Imara to Present at Upcoming Investor Conferences

Citi 16th Annual BioPharma Virtual Conference, H.C. Wainwright 23rd Annual Global Investment Conference and Morgan Stanley 19th Annual Global Healthcare Conference Citi 16th Annual BioPharma Virtual Conference, H.C. Wainwright 23rd Annual Global Investment Conference and Morgan Stanley 19th Annual G…

Imara Reports Second Quarter 2021 Financial Results and Business Highlights

Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021

Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease

Interim analysis expected in fourth quarter of 2021 and primary endpoint readout now expected in first quarter of 2022 Interim analysis expected in fourth quarter of 2021 and primary endpoint readout now expected in first quarter of 2022

Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights

BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host…

Imara Announces Pricing of Public Offering

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, announced the pricing of i…
Show more

Imara Blogs

Imara Appoints Joelle Lufkin, M.P.H., as Senior Vice President of Development

Brings proven drug development and clinical operations leadership to the company’s continued clinical development of IMR-687 for sickle cell disease and beta-thalassemia Boston, Mass., February 6, 2020 – Imara Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializi…

Imara Submits Confidential Draft Registration Statement for Proposed Initial Public Offering

Boston, Mass., September 13, 2019 – Imara Inc. today announced that it has previously confidentially submitted a draft registration statement on Form S-1 to the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares t…

Imara Expands Management Team and Strengthens Expertise Across Strategic Functions as it Advances IMR-687 for Sickle Cell Disease and Beta Thalassemia

Company has appointed VPs of Program Management, Clinical Development, Technical Operations, Quality Assurance and Development Operations Cambridge, Mass., August 13, 2019 – Imara Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat…

Imara Presented Positive, Interim Phase 2a Data on IMR-687 for the Treatment of Sickle Cell Disease at the 24th Congress of the European Hematology Association

Company encouraged by interim 13-week data in trial designed to assess the safety and tolerability of IMR-687 and explore the potential efficacy of IMR-687 on clinical outcome measures relevant to sickle cell disease Cambridge, Mass., June 18, 2019 – Imara Inc., a clinical-stage biopharmaceutical co…

Imara to Present at the 24th Congress of the European Hematology Association

Cambridge, Mass., June 7, 2019 – Imara Inc., a clinical-stage biopharmaceutical company developing novel therapies for people living with sickle cell disease and other serious, inherited blood disorders, today announced that the company will deliver an oral presentation on IMR-687 at the 24th Congre…

Imara Announces FDA Fast Track Designation for IMR-687 for the Treatment of Sickle Cell Disease

Cambridge, Mass., May 29, 2019 – Imara, Inc., a clinical-stage biopharmaceutical company focused on sickle cell disease and other hemoglobinopathies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to IMR-687, the company’s lead product candidate f…

Imara Frequently Asked Questions

  • When was Imara founded?

    Imara was founded in 2015.

  • Who are Imara key executives?

    Imara's key executives are Rahul D. Ballal, Rahul Ballal and Kenneth Attie.

  • How many employees does Imara have?

    Imara has 20 employees.

  • Who are Imara competitors?

    Competitors of Imara include Cassava Sciences, Strand Therapeutics and ReViral.

  • Where is Imara headquarters?

    Imara headquarters is located at 116 Huntington Ave 6th floor, Boston.

  • Where are Imara offices?

    Imara has an office in Boston.

  • How many offices does Imara have?

    Imara has 1 office.